ADRX · Insider Trading
ADARx Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ADRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-30 | Erez Chimovits | Director | MIXED | +9,292,025 | +$1.05M |
| 2026-09-30 | Carl L Gordon | Director | MIXED | +24,205,789 | +$16.15M |
| 2026-09-30 | OrbiMed Israel GP II, L.P. | Director | MIXED | +121,028,945 | +$80.75M |
| 2026-09-29 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | MIXED | +9,936,661 | +$27.20M |
| 2026-09-29 | Simeon George | Director | MIXED | +9,936,661 | +$27.20M |
| 2026-09-29 | LAV Biosciences Fund V, L.P. | 10%+ Owner | C | +35,575,965 | — |
| 2026-09-28 | Zhen Li | President and CEO | A | +1,024,152 deriv. | — |
| 2026-09-28 | Robert William Ackles | Chief People Officer | A | +85,346 deriv. | — |
| 2026-09-28 | Ryan Fisk | CFO and CBO | A | +170,692 deriv. | — |
| 2026-09-28 | Rui (NMN) Zhu | Chief Technology Officer | A | +512,076 deriv. | — |
| 2026-09-28 | Alan Robert MacLeod | Chief Scientific Officer | A | +170,692 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| LAV Biosciences Fund V, L.P. | 10%+ Owner | 11,397,049 | — |
| Carl L Gordon | Director | 8,974,061 | — |
| Erez Chimovits | Director | 7,127,019 | — |
| SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | 3,334,938 | — |
| Simeon George | Director | 1,953,505 | — |
| OrbiMed Israel GP II, L.P. | Director | 588,235 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.